- About Us
- Guidelines
-
The Author ensures that the research has been conducted responsibly and ethically with adherence to all relevant regulations. read more..
- For Authors
- For Reviewer
- Manuscript Guidelines
- Membership
-
- Journals
- Reprints
- e-Books
- Videos
- Indexing
- Contact Us
COVID-19
- Submissions
Abstract
Gastroenterology Medicine & Research
Anti-CTLA-4 Induced Inflammatory Bowel Disease: Is There A More Etiological Treatment? Lessons From CTLA-4 Haploinsufficiency
-
Open or Close Athina Theocharidou and Georgios Germanidis*
First Department of Internal Medicine, Gastroenterology and Hepatology Section, AHEPA Hospital of the Aristotle University Medical School, Thessaloniki, Greece
*Corresponding author: Georgios Germanidis, First Department of Internal Medicine, Gastroenterology and Hepatology Section,AHEPA Hospital of the Aristotle University Medical School,1, St. Kyriakidi Str., 546 36 Thessaloniki, Greece
Submission: May 10, 2018 ; Published: July 05, 2018
ISSN 2637-7632Volume1 Issue5
Abstract
We read with great interest the article by Bamias G et al. [1] entitled “Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy’’ [1], and we would like to address some issues regarding possible future use of a more etiological treatment for this colitis, namely abatacept. The immunological characteristics of anti-CTLA-4 and anti-PD-1-related colitis have been up to now poorly described [1,2].
Editor In Chief
.jpg)
Signup for Newsletter
Quick Links
Editorial Board Registrations
Submit your Article
Best Paper of the Volume
Reprints
Refer a Friend
Advertise With UsOur Recent Edition
.jpg)
Top Editors
.jpg)
.bmp)
.jpg)
.png)
.jpg)
.png)
.png)
.png)
Financial Support
Sponsors
Latest e-Books
Latest Video
a Creative Commons Attribution 4.0 International License. Based on a work at www.crimsonpublishers.com.
Best viewed in 
| Above IE 9.0 version